As of 06 Nov 2026 13:46 UTC. Status is always as stated in the latest recorded notice; the sources do not publish resolution, so nothing on this page says a medicine is back — see methodology.
Presentations, as stated in the latest recorded notice
Each line is re-expressed from MSN/2025/021 (07 Apr 2025): the product named, the status the source stated, and the expected-back phrase kept as written. Not the source's sentence, and not an observation of stock.
| Presentation | Status, as stated | Expected back, as stated | Stated in |
|---|---|---|---|
| Triamcinolone acetonide 10mg/ml (Adcortyl® multi-dose vial) and 40mg/ml (Kenalog® vials) suspension for injectionaffected product · inferred from phrasing | Discontinued, as stated | — not stated for this line | notice of 07 Apr 2025 |
| Dexamethasone sodium phosphate 3.3mg/ml and 3.8mg/ml injectionsnamed by the source as remaining available · inferred from phrasing | Stated as available | — not stated for this line | notice of 07 Apr 2025 |
| Hydrocortisone sodium succinate 100mg powder for solution for injectionnamed by the source as remaining available · inferred from phrasing | Stated as available | — not stated for this line | notice of 07 Apr 2025 |
| Methylprednisolone sodium succinate (Solu-Medrone®) 500mg and 1g injection and methylprednisolone acetate (Depo-Medrone®) 40mg/ml injectionnamed by the source as remaining available · inferred from phrasing | Stated as available | — not stated for this line | notice of 07 Apr 2025 |
Protocol in force
No Serious Shortage Protocol matched to this name is in force on the NHSBSA register. Matching is by name until identifier coding lands.
Named in the source as remaining available
- Dexamethasone sodium phosphate 3.3mg/ml and 3.8mg/ml injections — named by the source as remaining available (inferred from phrasing)
- Hydrocortisone sodium succinate 100mg powder for solution for injection — named by the source as remaining available (inferred from phrasing)
- Methylprednisolone sodium succinate (Solu-Medrone®) 500mg and 1g injection and methylprednisolone acetate (Depo-Medrone®) 40mg/ml injection — named by the source as remaining available (inferred from phrasing)
Only names the source itself listed, as it listed them (source post ↗). No substitution, dosing or counselling advice is given here or implied.
Identifiers — Triamcinolone Acetonide
BNF chemical and SNOMED identifiers from NHSBSA Prescription Cost Analysis (Open Government Licence), matched by name (presentation name), confidence 0.90 — grouping under review where marked Release Jul 2026.
BNF SNOMED mapping, NHSBSA Copyright 2026; Prescription Cost Analysis (PCA) Monthly Administrative Data, NHSBSA Copyright 2026. This information is licenced under the terms of the Open Government Licence.
History
Notified short 2 times on record since 2024. We record when a shortage is declared, not when stock returns — the source doesn't publish that. An update sharing a reference counts as one episode.
| Issued | Notice | Kind | Tier | Reference |
|---|---|---|---|---|
| 07 Apr 2025 | Medicine Supply Notification: Triamcinolone acetonide 10mg/ml (Adcortyl® multi-dose vial) and 40mg/ml (Kenalog® vials) suspension for injection | Supply notification | Tier 2 | MSN/2025/021 |
| 18 Jun 2024 | Medicine Supply Notification: Triamcinolone acetonide suspension for injection vials (Kenalog® 40mg/1ml and Adcortyl® 50mg/5ml) | Supply notification | Tier 2 | MSN/2024/073 |
Also recorded under
No other name appears in this medicine's notice titles. Grouping is by the head name in each title; brand and generic names may still sit on separate pages until identifier coding refines it — see the A–Z.
Scotland — separate record
NHS Scotland issues its own Medicine Supply Alert Notices. These match this medicine's name; they are shown beside, never added to, the England record.
- MSAN(2025)16 Triamcinolone acetonide 10mg/ml (Adcortyl® ampoules) and 40mg/ml · issued 11 Apr 2025 · valid until noted products are being discontinued, as stated · matched by name PDF ↗